{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:08:45Z","timestamp":1791835725324,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10620-026-09778-w","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:29:16Z","timestamp":1772447356000},"page":"3302-3312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of 5-Aminosalicylate Dose Reduction or Withdrawal on Prognosis in Patients with Ulcerative Colitis Receiving Advanced Therapy: A Multicenter Retrospective Cohort Study"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1217-3790","authenticated-orcid":false,"given":"Yasuki","family":"Sano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5800-1769","authenticated-orcid":false,"given":"Naoto","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6327-5322","authenticated-orcid":false,"given":"Yuka","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8488-4584","authenticated-orcid":false,"given":"Naohiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9601-4065","authenticated-orcid":false,"given":"Yusuke","family":"Honzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0013-6808","authenticated-orcid":false,"given":"Eiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9268-3299","authenticated-orcid":false,"given":"Norimasa","family":"Fukata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3424-3142","authenticated-orcid":false,"given":"Kazuichi","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6911-7686","authenticated-orcid":false,"given":"Masaaki","family":"Shimatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-3243","authenticated-orcid":false,"given":"Makoto","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"9778_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1586\/ecp.12.2","volume":"5","author":"M Ham","year":"2012","unstructured":"Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol 2012;5:113\u2013123. https:\/\/doi.org\/10.1586\/ecp.12.2.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"9778_CR2","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/apt.14688","volume":"47","author":"P Sehgal","year":"2018","unstructured":"Sehgal P, Colombel JF, Aboubakr A, Narula N. Systematic review: safety of mesalazine in ulcerative colitis. Aliment Pharmacol Ther 2018;47:1597\u20131609. https:\/\/doi.org\/10.1111\/apt.14688.","journal-title":"Aliment Pharmacol Ther"},{"key":"9778_CR3","first-page":"CD000544","volume":"8","author":"A Murray","year":"2020","unstructured":"Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;8:CD000544.","journal-title":"Cochrane Database Syst Rev"},{"key":"9778_CR4","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462\u20132476. https:\/\/doi.org\/10.1056\/NEJMoa050516.","journal-title":"N Engl J Med"},{"key":"9778_CR5","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/gut.2010.221127","volume":"60","author":"W Reinisch","year":"2011","unstructured":"Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780\u2013787. https:\/\/doi.org\/10.1136\/gut.2010.221127.","journal-title":"Gut"},{"key":"9778_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96-109.e1. https:\/\/doi.org\/10.1053\/j.gastro.2013.06.010.","journal-title":"Gastroenterology"},{"key":"9778_CR7","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2019;381:1201\u20131214. https:\/\/doi.org\/10.1056\/NEJMoa1900750.","journal-title":"N Engl J Med"},{"key":"9778_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699\u2013710. https:\/\/doi.org\/10.1056\/NEJMoa1215734.","journal-title":"N Engl J Med"},{"key":"9778_CR9","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376:1723\u20131736. https:\/\/doi.org\/10.1056\/NEJMoa1606910.","journal-title":"N Engl J Med"},{"key":"9778_CR10","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan BG, Danese S, Loftus EV Jr et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet 2021;397:2372\u20132384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00666-8.","journal-title":"Lancet"},{"key":"9778_CR11","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Feagan BG, Loftus EV Jr et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology 2020;158:2139-2149.e14. https:\/\/doi.org\/10.1053\/j.gastro.2020.02.030.","journal-title":"Gastroenterology"},{"key":"9778_CR12","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D'Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2023;388:2444\u20132455. https:\/\/doi.org\/10.1056\/NEJMoa2207940.","journal-title":"N Engl J Med"},{"key":"9778_CR13","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.2024.12414","volume":"332","author":"E Louis","year":"2024","unstructured":"Louis E, Schreiber S, Panaccione R et al. Risankizumab for ulcerative colitis: two randomized clinical trials. JAMA 2024;332:881\u2013897. https:\/\/doi.org\/10.1001\/jama.2024.12414.","journal-title":"JAMA"},{"key":"9778_CR14","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","volume":"167","author":"S Singh","year":"2024","unstructured":"Singh S, Murad MH, Fumery M et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology 2024;167:1307\u20131343. https:\/\/doi.org\/10.1053\/j.gastro.2024.10.001.","journal-title":"Gastroenterology"},{"key":"9778_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase H, Sato N, Mizuno N, Ikawa Y. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489\u2013526. https:\/\/doi.org\/10.1007\/s00535-021-01784-1.","journal-title":"J Gastroenterol"},{"key":"9778_CR16","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (stride) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021;160:1570\u20131583. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031.","journal-title":"Gastroenterology"},{"key":"9778_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0002-9343(02)01383-9","volume":"114","author":"S Kane","year":"2003","unstructured":"Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003;114:39\u201343. https:\/\/doi.org\/10.1016\/S0002-9343(02)01383-9.","journal-title":"Am J Med"},{"key":"9778_CR18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1136\/gutjnl-2018-317021","volume":"68","author":"RC Ungaro","year":"2019","unstructured":"Ungaro RC, Limketkai BN, Jensen CB et al. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Gut 2019;68:977\u2013984. https:\/\/doi.org\/10.1136\/gutjnl-2018-317021.","journal-title":"Gut"},{"key":"9778_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/apt.18102","volume":"60","author":"J Seo","year":"2024","unstructured":"Seo J, Lee HJ, Lee HS et al. Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: a nationwide population-based study. Aliment Pharmacol Ther 2024;60:389\u2013400. https:\/\/doi.org\/10.1111\/apt.18102.","journal-title":"Aliment Pharmacol Ther"},{"key":"9778_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf001","author":"Y Nishida","year":"2025","unstructured":"Nishida Y, Hosomi S, Kobayashi Y et al. Impact of 5-aminosalicylic acid on ustekinumab in inflammatory bowel disease: a retrospective medical claims analysis. Inflamm Bowel Dis. 2025. https:\/\/doi.org\/10.1093\/ibd\/izaf001.","journal-title":"Inflamm Bowel Dis"},{"key":"9778_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/apt.15771","volume":"52","author":"TP Chapman","year":"2020","unstructured":"Chapman TP, Frias Gomes C, Louis E, Colombel JF, Satsangi J. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:73\u201384. https:\/\/doi.org\/10.1111\/apt.15771.","journal-title":"Aliment Pharmacol Ther"},{"key":"9778_CR22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s10620-018-5378-8","volume":"64","author":"M Bajpai","year":"2019","unstructured":"Bajpai M, Shin JH, Maheshwari A et al. Effect of long-term mesalamine therapy on cancer-associated gene expression in colonic mucosa of patients with ulcerative colitis. Dig Dis Sci 2019;64:740\u2013750. https:\/\/doi.org\/10.1007\/s10620-018-5378-8.","journal-title":"Dig Dis Sci"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09778-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09778-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09778-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:02:17Z","timestamp":1787540537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09778-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["9778"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09778-w","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Kansai Medical University (approval number: 2022136) and was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An opt-out approach was used for consent as this was a retrospective observational study. Patients were allowed to refuse participation via the institutional website.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study uses anonymized retrospective data with no identifiable patient information.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}